FDA 483 - Zhejiang Guobang Pharmaceutical Co., Ltd - March 03, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Zhejiang Guobang Pharmaceutical Co., Ltd. revealed significant deficiencies in laboratory controls related to their water systems used in drug substance manufacturing. The firm lacked scientifically justified specifications and test procedures for (b)(4) water, failing to ensure its identity, quality, and purity. This included inadequate microbial monitoring, failure to detect potential biofilms, and insufficient speciation of microorganisms in their water system.
ID · 940729c8-9f67-4a2b-b16b-31436888e32a